Europe Point-of-care Testing (POCT) Market Size 2026-2030
The europe point-of-care testing (poct) market size is valued to increase by USD 8.25 billion, at a CAGR of 8.8% from 2025 to 2030. Shift toward rapid diagnostics over traditional labs will drive the europe point-of-care testing (poct) market.
Major Market Trends & Insights
- By Type - OTC testing segment was valued at USD 9.25 billion in 2024
- By Application - Blood glucose testing segment accounted for the largest market revenue share in 2024
Market Size & Forecast
- Market Opportunities: USD 12.98 billion
- Market Future Opportunities: USD 8.25 billion
- CAGR from 2025 to 2030 : 8.8%
Market Summary
- The point-of-care testing (POCT) market in Europe is defined by a decisive shift toward decentralized healthcare, driven by an aging population and the need for efficient chronic disease management. Key trends include the integration of artificial intelligence for data-driven diagnostics, which enhances diagnostic precision and supports remote patient monitoring.
- Technologies such as syndromic testing and molecular point-of-care devices are becoming instrumental in this transition. For instance, a hospital network can implement these advanced systems in emergency departments to streamline patient triage and improve bed allocation, achieving significant operational efficiencies. This evolution is underpinned by innovations in microfluidics and biosensors, enabling the development of compact and sophisticated point-of-care (POC) tests.
- However, the stringent in vitro diagnostic regulation (IVDR) presents a notable challenge, mandating extensive clinical evidence and robust post-market surveillance. This regulatory framework significantly impacts development timelines and investment strategies for companies introducing novel over-the-counter (OTC) testing and prescription-based testing solutions, requiring a strategic approach to compliance and market entry.
- The market continues to advance through technologies like high-sensitivity troponin assays and continuous glucose monitoring (CGM).
What will be the Size of the Europe Point-of-care Testing (POCT) Market during the forecast period?
Get Key Insights on Market Forecast (PDF) Request Free Sample
How is the Europe Point-of-care Testing (POCT) Market Segmented?
The europe point-of-care testing (poct) industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2026-2030, as well as historical data from 2020-2024 for the following segments.
- Type
- OTC testing
- Prescription-based testing
- Application
- Blood glucose testing
- Infectious diseases testing
- Cardiac markers testing
- Pregnancy and fertility testing
- Others
- Platform
- Lateral flow assays
- Immunoassays
- Molecular diagnostics
- Dipsticks
- Others
- Geography
- Europe
- Germany
- France
- Italy
- Europe
By Type Insights
The otc testing segment is estimated to witness significant growth during the forecast period.
The over-the-counter (OTC) testing segment is reshaping health management by empowering consumers with direct access to diagnostics.
This shift toward self-directed care is enabled by user-friendly formats, including advanced lateral flow assays and electrochemical sensors, which deliver reliable results outside of clinical environments.
Growth is fueled by the rising need for frequent screening for both chronic and infectious diseases, aligning with a broader push for preventive wellness technology.
The integration with digital health platforms further enhances the value proposition, as mobile applications can assist in real-time data interpretation, improving result accuracy by over 15% compared to unassisted readings.
This trend toward consumer health monitoring is a cornerstone of modern, patient-centric models, facilitating early detection and proactive health management. The convenience of at-home sample collection and rapid diagnostics drives adoption of these point-of-care (POC) tests.
The OTC testing segment was valued at USD 9.25 billion in 2024 and showed a gradual increase during the forecast period.
Market Dynamics
Our researchers analyzed the data with 2025 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
- The strategic implementation of point-of-care testing is reshaping healthcare delivery, with a primary focus on improving diagnostic speed and accessibility. A key application is point of care testing for infectious diseases, where rapid results are crucial for containment. Simultaneously, for chronic conditions, the emphasis is on continuous glucose monitoring system accuracy and the convenience of rapid coagulation testing at home.
- The technology enabling this shift includes molecular diagnostics at point of care, which offer high sensitivity. Innovation in the lateral flow assay development process continues to yield cost-effective solutions, while microfluidics in point of care devices and lab-on-a-chip technology for urinalysis enable miniaturization.
- Navigating the impact of IVDR on POCT devices remains a central challenge, alongside the persistent challenges in POCT clinical validation. Ensuring point of care cardiac marker sensitivity, especially with high-sensitivity troponin point of care assays, is critical in emergency settings.
- The reliability of over the counter diagnostic test reliability is paramount for consumer trust, while AI in POCT data analysis promises to enhance interpretation. Facilities that focus on point of care testing workflow optimization through telehealth integration with POCT results report patient processing times nearly twice as fast as those using traditional labs.
- This efficiency is vital for managing decentralized diagnostics for chronic conditions and deploying syndromic testing panels for clinics. Furthermore, the market is seeing growth in prescription POCT for respiratory infections and enhanced self-monitoring blood glucose device connectivity, powered by advanced biosensor technology for metabolic monitoring.
What are the key market drivers leading to the rise in the adoption of Europe Point-of-care Testing (POCT) Industry?
- A significant market driver is the industry-wide shift toward rapid diagnostics over traditional laboratory testing, fueled by a growing demand for faster, decentralized healthcare solutions.
- Market growth is primarily fueled by a systemic shift toward rapid, decentralized healthcare solutions.
- The adoption of near-patient testing allows for a turnaround time reduction of up to 90% compared to traditional centralized labs, a critical factor in emergency and primary care.
- This transition is further accelerated by the expansion of telemedicine and remote patient monitoring, where real-time glycemic assessment and other biomarker detection are essential.
- For instance, the use of continuous glucose monitoring (CGM) devices within home-based care programs for the geriatric population has been linked to a 20% decrease in related emergency hospital visits.
- This synergy between rapid diagnostics and virtual wards, supported by robust health technology assessment, enhances clinical workflow efficiency and patient outcomes, solidifying the trend toward decentralized diagnostics.
What are the market trends shaping the Europe Point-of-care Testing (POCT) Industry?
- The adoption of artificial intelligence and data analytics in point-of-care testing is an emerging and transformative trend. This shift is driven by the growing need for faster, more accurate diagnostics and improved patient outcomes.
- Key trends are reshaping the point-of-care testing landscape, driven by technological innovation and a demand for accessible diagnostics. The adoption of AI is enabling data-driven diagnostics that improve diagnostic precision by over 15% compared to manual methods.
- Advancements in microfluidics and lab-on-a-chip technologies are facilitating the creation of miniaturized multiplex assays, which can reduce sample volume requirements by more than 50%. This innovation supports the expansion of over-the-counter (OTC) testing, a cornerstone of modern consumer health monitoring and preventive wellness technology.
- The rise of user-friendly formats and digital health integration aligns with patient-centric models, making CLIA-waived devices and non-invasive monitoring solutions more prevalent in home-based care and telehealth consultations.
What challenges does the Europe Point-of-care Testing (POCT) Industry face during its growth?
- The complexity of regulatory compliance under the EU In Vitro Diagnostic Regulation (IVDR) presents a significant market challenge, creating longer approval timelines and higher costs for manufacturers.
- Significant challenges constrain the market, led by the stringent in vitro diagnostic regulation (IVDR), which has increased the proportion of devices requiring notified body review from approximately 15% to over 80%. This complexity elevates compliance costs and lengthens approval timelines for innovations in molecular point-of-care and other advanced diagnostics.
- Persistent concerns regarding lab-quality performance and analytical accuracy also affect market trust, as product recalls can hinder adoption. Ensuring diagnostic precision across diverse settings is a constant focus, particularly for syndromic panel testing platforms and sensitive biosensors.
- Failure to meet rigorous clinical validation standards can delay market entry, creating a challenging environment for manufacturers focused on emergency use authorizations and new testing solutions.
Exclusive Technavio Analysis on Customer Landscape
The europe point-of-care testing (poct) market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the europe point-of-care testing (poct) market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape of Europe Point-of-care Testing (POCT) Industry
Competitive Landscape
Companies are implementing various strategies, such as strategic alliances, europe point-of-care testing (poct) market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
A. Menarini Industrie Farma - Offerings include high-speed, precision diagnostic instruments for clinical chemistry, diabetes management, and point-of-care testing applications.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- A. Menarini Industrie Farma
- Abbott Laboratories
- ACON Laboratories Inc.
- Becton Dickinson and Co.
- BioMerieux SA
- Chembio Diagnostics Inc.
- Danaher Corp.
- LifeScan IP Holdings LLC
- Nova Biomedical Corp.
- OraSure Technologies Inc.
- PHC Holdings Corp.
- Siemens Healthineers AG
- Sinocare Inc.
- Sysmex Corp.
- Thermo Fisher Scientific Inc.
- Trinity Biotech Plc
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Europe point-of-care testing (poct) market
- In late 2024, Abbott Laboratories obtained the CE Mark for the Lingo system, a biosensor designed for consumer health monitoring within the European market.
- In late 2024, Becton Dickinson and Company and BioMerieux SA strengthened their partnership to advance automation and data connectivity for microbiology diagnostic applications.
- In April 2025, the National Health Service (NHS) in the UK rolled out N-Tidal Diagnose, the first AI-based point-of-care test for diagnosing chronic obstructive pulmonary disease (COPD) without spirometry.
- In May 2025, Roche Diagnostics presented a strategic plan for integrating the LumiraDx handheld instrument to expand decentralized testing capabilities in European community health centers.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Europe Point-of-care Testing (POCT) Market insights. See full methodology.
| Market Scope | |
|---|---|
| Page number | 219 |
| Base year | 2025 |
| Historic period | 2020-2024 |
| Forecast period | 2026-2030 |
| Growth momentum & CAGR | Accelerate at a CAGR of 8.8% |
| Market growth 2026-2030 | USD 8247.1 million |
| Market structure | Fragmented |
| YoY growth 2025-2026(%) | 8.2% |
| Key countries | Germany, France, Italy, UK and Rest of Europe |
| Competitive landscape | Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Research Analyst Overview
- The point-of-care testing market's evolution is marked by a convergence of advanced technologies and shifting healthcare models. Foundational platforms like lateral flow assays and immunoassays are now complemented by sophisticated molecular diagnostics, microfluidics, and lab-on-a-chip technologies, enabling a new generation of point-of-care (POC) tests.
- These innovations, incorporating biosensors and electrochemical sensors, support a wide range of applications, from continuous glucose monitoring (CGM) and self-monitoring of blood glucose (SMBG) to high-sensitivity troponin assays for cardiac emergencies and routine coagulation testing.
- The market is bifurcated into over-the-counter (OTC) testing for consumers and prescription-based testing for clinical settings, both driving the overarching trend toward decentralized testing and near-patient testing.
- For boardroom consideration, the stringent in vitro diagnostic regulation (IVDR) has transformed compliance into a major budgetary item, demanding significant investment in clinical evidence for all devices, including those using isothermal amplification, chemiluminescence, or fluorescence-based detection. This regulatory shift directly impacts R&D pipelines and go-to-market strategies.
- The adoption of syndromic testing panels with multiplex assays has been shown to reduce diagnostic uncertainty by up to 60%, a crucial factor in improving antimicrobial stewardship and patient outcomes.
What are the Key Data Covered in this Europe Point-of-care Testing (POCT) Market Research and Growth Report?
-
What is the expected growth of the Europe Point-of-care Testing (POCT) Market between 2026 and 2030?
-
USD 8.25 billion, at a CAGR of 8.8%
-
-
What segmentation does the market report cover?
-
The report is segmented by Type (OTC testing, and Prescription-based testing), Application (Blood glucose testing, Infectious diseases testing, Cardiac markers testing, Pregnancy and fertility testing, and Others), Platform (Lateral flow assays, Immunoassays, Molecular diagnostics, Dipsticks, and Others) and Geography (Europe)
-
-
Which regions are analyzed in the report?
-
Europe
-
-
What are the key growth drivers and market challenges?
-
Shift toward rapid diagnostics over traditional labs, Regulatory compliance complexity under EU IVDR
-
-
Who are the major players in the Europe Point-of-care Testing (POCT) Market?
-
A. Menarini Industrie Farma, Abbott Laboratories, ACON Laboratories Inc., Becton Dickinson and Co., BioMerieux SA, Chembio Diagnostics Inc., Danaher Corp., LifeScan IP Holdings LLC, Nova Biomedical Corp., OraSure Technologies Inc., PHC Holdings Corp., Siemens Healthineers AG, Sinocare Inc., Sysmex Corp., Thermo Fisher Scientific Inc. and Trinity Biotech Plc
-
Market Research Insights
- Market dynamics are increasingly shaped by the expansion of telehealth consultations and the critical need for remote patient monitoring. The integration of point-of-care testing into virtual wards has proven effective, contributing to a reduction in hospital readmissions by up to 20% in certain patient cohorts.
- This synergy between digital health integration and diagnostics is pivotal for achieving greater clinical workflow efficiency. Facilities that adopt data-driven diagnostics report a significant turnaround time reduction of over 30% for critical tests. Furthermore, the rise of consumer health monitoring through over-the-counter (OTC) testing aligns with a patient-centric model, empowering individuals to take a proactive role in their health.
- This trend, supported by CLIA-waived devices suitable for home-based care, reflects a fundamental shift in how diagnostic services are delivered and consumed across the healthcare ecosystem.
We can help! Our analysts can customize this europe point-of-care testing (poct) market research report to meet your requirements.